Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

VBI Vaccines ($VBIV) announced that the FDA has approved its Investigational New Drug Application (IND) for immunotherapy candidate VBI-1901. The drug candidate is seeking approval as the potential treatment of Glioblastoma Multiforme (GBM), a common and aggressive type of malignant brain tumor. The IND enables VBI to initiate a multi-center Phase I/2a clinical study evaluating VBI-1901 in patients with recurrent GBM in the second half of this year.
The company stock jumped over 12 percent in after hours trading session. It has gained 14 percent this year so far.

Cocrystal Pharma ($COCP) announced positive data from a Phase 1a/1b study assessing the safety, tolerability, pharmacokinetics and antiviral activity of HCV candidate CC-31244. The company intends to initiate Phase 2 development for the drug candidate. Stage 1a involved 30 healthy volunteers who received single doses (20 mg - 400 mg) of CC-31244 and 12 healthy volunteers who received multiple doses (200 mg or 400 mg) for seven days. In Stage 1b, 15 patients with HCV genotype 1 infection received CC-31244 for seven days.
The stock reacted positively to the news and jumped over 13 percent in its previous trading session, trimming its Years to Date losses to 45 percent.

 

Centene ($CNC) announced its plan to sell Obamacare products in Nevada, starting next year. The company said that its SilverSummit Healthplan will extend to all 17 counties of Nevada, including the "bare counties" that were expected not to have coverage by any other health insurers in 2018.

Supernus Pharmaceuticals ($SUPN) received a favorable ruling from a New Jersey district court in a patent infringement case involving antiseizure med Oxtellar XR (oxcarbazepine) against TWi Pharmaceuticals.

Amicus Therapeutics ($FOLD) announced receiving the Australian Therapeutic Goods Administration approval for oral Galafold (migalastat) for the long-term treatment of patients at least 16 years old with Fabry disease who have an amenable mutation.

Alexion Pharmaceuticals ($ALXN) announced receiving three new patents No. 9,732,149, No. 9,718,880 and No. 9,725,504 from the USPTO. These patents cover the composition of matter of eculizumab (Soliris), pharmaceutical formulations of eculizumab and methods of treating paroxysmal nocturnal hemoglobinuria (PNH) with eculizumab, respectively. The patent protection will remain effective until 2027.

 

Cancer Genetics ($CGIX) announced that it will acquire vivoPharm, an Australia-based contract research organization, for $12 million in cash. The company expects the acquisition to boost its position in oncology drug discovery, specifically in immuno-oncology. The transaction will be paid with $1.2 million in cash and Cancer Genetics common stock.

Surmodics ($SRDX) announced inking a new deal with Baim Institute for Clinical Research. The deal pertains to the TRANSCEND clinical trial for the SurVeil drug-coated balloon (DCB) for the treatment of peripheral artery disease in the upper leg. The total cost of the trial is expected to be in the range of $32 million to 40 million over the course of next several years.

Brokerage Action Company Rating
Oppenheimer Holdings Reiterates Advance Auto Parts (AAP)
Hold
Barclays PLC Reiterates Apple (AAPL)
Hold
Barclays PLC Reiterates Automatic Data Processing (ADP)
Equal Weight
FBR & Co Upgrades American Eagle Outfitters (AEO)
Neutral -> Buy
Stifel Nicolaus Upgrades Antero Midstream Partners LP (AM)
Hold -> Buy
Canaccord Genuity Reiterates Advanced Micro Devices (AMD)
Buy
SunTrust Banks Initiates Amazon.com (AMZN)
Buy

Gainers (% price change)Last TradeChangeMkt CapImmunoGen, Inc.IMGN6.28+0.56 (9.79%)562.67MCorcept Therapeutics Inc.CORT14.87+0.87 (6.21%)1.69BProgenics PharmaceuticalsPGNX5.56+0.28 (5.30%)390.70MChina Cord Blood CorpCO12.88+0.62 (5.06%)1.55BBioDelivery Sciences IntlBDSI3.20+0.15 (4.92%)177.52MLosers (% price change)Omeros CorporationOMER22.52-2.09 (-8.49%)1.01BCompugen Ltd. (USA)CGEN3.10-0.25 (-7.46%)158.03MCommunity Health SystemsCYH6.88-0.47 (-6.39%)789.54MBioScrip IncBIOS3.10-0.15 (-4.62%)395.17MLandauer IncLDR59.65-2.85 (-4.56%)574.94MMost Actives (dollar volume)Intuitive Surgical, Inc.ISRG985.37+20.81 (2.16%)36.61BPfizer Inc.PFE33.38+0.07 (0.21%)198.78BJohnson & JohnsonJNJ133.38-0.10 (-0.07%)357.99BTeva PharmaceuticalTEVA17.97+0.81 (4.72%)18.38BMerck & Co., Inc.MRK62.50-0.17 (-0.27%)170.46B